Longevity Health (XAGE) announced that it has received a favorable decision from the Nasdaq Hearings Panel granting the company’s request to continue its listing on Nasdaq subject to the satisfaction of the Nasdaq initial listing rules for the combined company following the proposed merger with 20/20 BioLabs on or before September 2. This decision follows the panel’s review of the company’s recent business developments, financial disclosures, and proposed merger with 20/20. As part of its strategic plan, Longevity presented its intention to merge with 20/20 and effect a 1-for-30 reverse stock split to address Nasdaq’s listing requirements. The company filed the S-4 registration statement for the proposed merger on May 8 and effected the reverse stock split on May 12.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAGE:
- Longevity Health reports unaudited Q1 revenue $663,000, up 8% year-over-year
- Longevity Health Holdings Inc trading halted, news pending
- Longevity Health Implements Reverse Stock Split
- Longevity Health announces 1-for-30 reverse stock split
- Longevity Health executes merger agreement with 20/20 Biolabs
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue